Cargando…

Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies

Targeting two unique antigens with a single bispecific antibody is an attractive approach with potential broad therapeutic applicability. However, the production of heterodimeric bispecific antibodies (bsAbs) presents a challenge, requiring the co-expression and accurate pairing of two distinct heav...

Descripción completa

Detalles Bibliográficos
Autores principales: Bönisch, Maximilian, Sellmann, Carolin, Maresch, Daniel, Halbig, Claudia, Becker, Stefan, Toleikis, Lars, Hock, Björn, Rüker, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914326/
https://www.ncbi.nlm.nih.gov/pubmed/28981885
http://dx.doi.org/10.1093/protein/gzx044
_version_ 1783316694905651200
author Bönisch, Maximilian
Sellmann, Carolin
Maresch, Daniel
Halbig, Claudia
Becker, Stefan
Toleikis, Lars
Hock, Björn
Rüker, Florian
author_facet Bönisch, Maximilian
Sellmann, Carolin
Maresch, Daniel
Halbig, Claudia
Becker, Stefan
Toleikis, Lars
Hock, Björn
Rüker, Florian
author_sort Bönisch, Maximilian
collection PubMed
description Targeting two unique antigens with a single bispecific antibody is an attractive approach with potential broad therapeutic applicability. However, the production of heterodimeric bispecific antibodies (bsAbs) presents a challenge, requiring the co-expression and accurate pairing of two distinct heavy and light chain units. Several undesirable by-products can be formed in the production process, including heavy chain homodimers and non-cognate light chain pairings. Although additional downstream purification methods exist, they are often time consuming and restrict practical large-scale production. In this study, we identify and validate novel Fab interface mutations that increase cognate light chain pairing efficiencies within heterodimeric bsAbs. Importantly, the variable domains remain unaltered as interface mutations were restricted to the C(H)1 and C(L) domains. We performed several biochemical assays to demonstrate that the novel engineered interfaces do not adversely impact bispecific antibody expression, stability, affinity and biological function. The designs reported here can easily be applied in a generic manner to use existing antibodies as building blocks for bsAbs which will help to accelerate the identification and production of next generation bispecific antibody therapeutics.
format Online
Article
Text
id pubmed-5914326
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-59143262018-05-04 Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies Bönisch, Maximilian Sellmann, Carolin Maresch, Daniel Halbig, Claudia Becker, Stefan Toleikis, Lars Hock, Björn Rüker, Florian Protein Eng Des Sel Original Article Targeting two unique antigens with a single bispecific antibody is an attractive approach with potential broad therapeutic applicability. However, the production of heterodimeric bispecific antibodies (bsAbs) presents a challenge, requiring the co-expression and accurate pairing of two distinct heavy and light chain units. Several undesirable by-products can be formed in the production process, including heavy chain homodimers and non-cognate light chain pairings. Although additional downstream purification methods exist, they are often time consuming and restrict practical large-scale production. In this study, we identify and validate novel Fab interface mutations that increase cognate light chain pairing efficiencies within heterodimeric bsAbs. Importantly, the variable domains remain unaltered as interface mutations were restricted to the C(H)1 and C(L) domains. We performed several biochemical assays to demonstrate that the novel engineered interfaces do not adversely impact bispecific antibody expression, stability, affinity and biological function. The designs reported here can easily be applied in a generic manner to use existing antibodies as building blocks for bsAbs which will help to accelerate the identification and production of next generation bispecific antibody therapeutics. Oxford University Press 2017-09 2017-08-31 /pmc/articles/PMC5914326/ /pubmed/28981885 http://dx.doi.org/10.1093/protein/gzx044 Text en © The Author 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bönisch, Maximilian
Sellmann, Carolin
Maresch, Daniel
Halbig, Claudia
Becker, Stefan
Toleikis, Lars
Hock, Björn
Rüker, Florian
Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies
title Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies
title_full Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies
title_fullStr Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies
title_full_unstemmed Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies
title_short Novel C(H)1:C(L) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies
title_sort novel c(h)1:c(l) interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914326/
https://www.ncbi.nlm.nih.gov/pubmed/28981885
http://dx.doi.org/10.1093/protein/gzx044
work_keys_str_mv AT bonischmaximilian novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies
AT sellmanncarolin novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies
AT mareschdaniel novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies
AT halbigclaudia novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies
AT beckerstefan novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies
AT toleikislars novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies
AT hockbjorn novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies
AT rukerflorian novelch1clinterfacesthatenhancecorrectlightchainpairinginheterodimericbispecificantibodies